PEPTIDE COMPARISON

AOD-9604 vs Semaglutide

An unapproved growth-hormone fragment compared with an extensively studied GLP-1 medicine.

QUICK ANSWER

AOD-9604 vs Semaglutide: the main difference.

Semaglutide has a mature clinical and regulatory record that AOD-9604 does not. Mechanistic weight-loss language cannot substitute for successful efficacy trials and product-specific approval.

Decision field	AOD-9604	Semaglutide
Human research	Obesity development without persuasive efficacy	Large randomized product-specific programs
Mechanism	Growth-hormone fragment	GLP-1 receptor agonist
FDA status	Not approved	Approved branded products for defined indications
Product evidence	No established obesity medicine	Evidence attaches to specific formulations, labels, and populations
Main boundary	Marketing often outpaces the clinical program	Compounded and counterfeit products are not FDA-approved equivalents

SOURCES

AOD-9604 vs Semaglutide sources.

FDA / 2024AOD-9604 Pharmacy Compounding Advisory Committee briefingU.S. FDA FDA / 2026Bulk substances that may present significant safety risksU.S. FDA WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2026Wegovy application and labeling recordU.S. FDA FDA / 2026FDA concerns with unapproved GLP-1 drugsU.S. FDA

AOD-9604 vs Semaglutide: the main difference.

AOD-9604 vs Semaglutide sources.

Questions related to AOD-9604 vs Semaglutide.

Compare the next decision.